A Roadmap for Curing Cancer, Alzheimer's, and Cardiovascular Disease

Cancer, dementia, and cardiovascular disease are responsible for almost two million deaths each year in the United States alone and represent the largest immediate threat to humanity. Over the last century, we have made spectacular advances that have transformed our society - splitting the atom, space travel, telecommunications, and the Internet - but with medical research focused mostly on science for the sake of science, it has yielded precious few cures. A Roadmap for Curing Cancer, Alzheimer's, and Cardiovascular Disease represents a 'first of its kind' effort to address both the reasons for this and to posit solutions to fix our broken system, in an effort to finally end this cure crisis. Dr. Marangos draws on 45 years of experience in every aspect of the biomedical R&D field, from basic drug discovery research at the NIH to the co-founding of five drug companies. He has published 252 research papers and edited four books on drug discovery, is co-inventor on 14 patents, and founded 'The Journal of Molecular Neuroscience'. He argues that from a development perspective, the regulatory, patent, and legal hurdles that force industry to pursue so-called 'me-too' drugs rather than cures for terminal diseases must be re-thought. Leadership accountability, strategy, focus, and urgency need to be re-evaluated, and major reforms to the NIH, FDA, and patent codes are proposed.to remedy these impediments to cures. Written for anyone frustrated with the seemingly endless threat of terminal disease, this book seeks to inform, energize, and provide the rationale for the public and industry stakeholders, as well as clinicians and researchers, to resurrect the physician-patient relationship and demand that we get serious about ridding society of this scourge on humanity. This work contains the views and opinions of the author and are in no way intended to harm the reputation of any person, agency, organization, or commercial entity discussed herein. www.cureterminaldisease.com - First comprehensive analysis of the failures in curing cancer, Alzheimer's, and cardiovascular disease with solutions proposed - Defines deficiencies in academic life science research, including conflicting incentives, QA/QC issues, and how to fix them - Provides a rationale for FDA reform especially as it relates to terminal disease drugs - Details how a reformed NIH, regulators, and industry can partner to form a NASA-type effort to speed cures of terminal diseases - Provides the first detailed roadmap for life science researchers to conquer terminal disease

Dr. Marangos is author of 252 peer-reviewed research papers on neurobiology, and 4 books - three by Academic Press (the Neurobiological Research series of volumes) and a fourth titled 'Emerging Strategies in Neuroprotection”. He is a founding editor of 'The Journal of Molecular Neuroscience” and inventor on 14 issued patents. He spent 13 years at the NIMH and was adjunct professor of neurochemistry at GW School of Medicine during that time. He is co-Founder of five Biotech firms with over 20 years of experience as CEO of both public and private life science companies. He has had extensive experience in all aspects of the pharmaceutical and biotechnology industries from bench to product. This coupled with his academic experience has provided a global perspective on the entire medical R&D enterprise, in particular its faults, and remedies to speed the quest for cures. https://www.wsj.com/articles/the-terminally-ill-need-more-than-the-right-to-try-1534200199?mod=searchresults&page=1&pos=1 https://www.prnewswire.com/news-releases/biomedica-partners-proposes-the-terminal-disease-act-300609691.html?tc=eml_cleartime http://thehill.com/opinion/healthcare/383484-right-to-try-efforts-have-have-been-timid-and-poorly-conceived https://www.prnewswire.com/news-releases/biomedica-partners-presents-major-reforms-in-terminal-disease-drug-development-at-magis-clinical-research-conference-300642731.html